Related Experiment Videos
Chemotherapy of leprosy
1Department of Dermatology, STD and Leprosy, Calcutta School of Tropical Medicine, Kolkata 700 073.
Journal of the Indian Medical Association
|May 6, 2005
Summary
World Health Organization Multidrug Therapy (MDT) regimens are highly effective in preventing leprosy relapse and reducing disabilities. Current treatment protocols for paucibacillary and multibacillary leprosy involve specific drug combinations and durations, with single-dose regimens for single-lesion cases.
Area of Science:
- Public Health
- Infectious Diseases
- Dermatology
Background:
- Leprosy, a chronic infectious disease, historically led to significant disabilities.
- World Health Organization (WHO) Multidrug Therapy (MDT) has been instrumental in managing leprosy cases.
- MDT regimens have demonstrated high success rates in preventing relapse and reducing disease prevalence.
Framework:
- Treatment for paucibacillary (PB) leprosy requires 6 months of therapy, including monthly rifampicin and daily dapsone.
- Multibacillary (MB) leprosy treatment involves adding clofazimine to the PB regimen.
- A single-dose regimen of rifampicin, ofloxacin, and minocycline is recommended for single-skin-lesion cases in adults.
Implementation:
- Specific dosages and administration schedules are outlined for both PB and MB leprosy.
- Dose adjustments for pediatric leprosy cases are considered.
- Clinical information relevant to leprosy treatment is summarized.
Implications:
- Successful MDT regimens have indirectly led to a marked reduction in leprosy-associated disabilities.
- Ongoing clinical trials aim to simplify leprosy therapy and shorten treatment durations.
- Further research may lead to improved treatment outcomes and patient management strategies.